-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In the early trading of August 23, the pharmaceutical stocks of Hong Kong stocks were active.
As of 10:38, GenScript Biotechnology rose 13.
56%, Zai Lab-SB rose 13.
33%, and Jiahe Bio-B also rose more than 10% , In addition, Nuohui Health-B and others have followed suit
.
Specifically, as of 10:38, GenScript Biotechnology has risen by 13.
56%, the current price is HK$35.
60, the average price is HK$34.
16, the current turnover is 234 million, the turnover rate is 0.
33%, and the total market value is 74.
449 billion
.
On the news, CRO concept stocks have been rising collectively recently.
GenScript Biotechnology recently announced that its biopharmaceutical contract R&D and production organization (CDMO) GenScript Biopharmaceuticals and Hefei Tiangang Immunopharmaceuticals have reached a new antibody drug project cooperation
.
According to the cooperation agreement, GenScript will provide Tiangang Immune with a complete integrated CDMO service from preclinical pharmaceutical development to IND application, and provide a variety of processes such as batch fed culture and perfusion culture to accelerate the IND process.
During the year, 10 CMC projects will be cooperated, and GenScript will be selected as a partner for future clinical and commercial production of related projects
.
JPMorgan Chase has published a report saying that the recent tightening of regulatory policies has no direct fundamental impact on China's healthcare industry, but it has also weakened the industry's market valuation, believing that the adjustment will create investment opportunities
.
The bank believes that the theme of medical regulation is clear, and it is expected to continue to focus on three major themes, namely promoting domestic innovation, improving quality, and improving affordability and accessibility for patients
.
The bank believes that pharmaceutical companies with strong innovation capabilities and management execution are expected to perform well in the long run, and continue to be optimistic about pharmaceutical companies with solid fundamentals and reasonable valuations
.
As of 10:38 on August 23, Zai Lab-SB rose 13.
33%, the current price was HK$1,063, the average price was HK$1,049.
43, the current turnover was 15.
92 million, the turnover rate was 0.
02%, and the total market value was 102.
3 billion
.
The semi-annual report recently disclosed by Zai Lab showed that the company's revenue in the first half of the year increased rapidly, with a year-on-year increase of 197%
.
The rapid growth of revenue is attributable to three products, namely Zele (Niraparib), Aipdun (tumor electric field treatment equipment), and Qingle (ripatinib)
.
Among them, Zele is the company's main product, which brought in sales revenue of US$35.
972 million in the first half of the year, accounting for 63.
1% of the total product revenue, an increase of 71.
8% compared to the same period in 2020
.
The rapid growth in sales is due to the fact that the product entered the National Medical Insurance Drug List (NRDL) in December last year.
The NRDL was officially implemented on March 1 this year.
As of June 30, the number of hospital admissions of Zele was seven times that of the previous one.
reached more than 800
.
It is understood that, in the face of increasingly fierce market competition, the company has confidence in Zele's huge applicable patient group, its ability to be taken orally once a day, and its ability to cross the blood-brain barrier.
Symptoms and opportunities for combination with other drugs
.
For example, Zele is now combined with tebotelimab for clinical research in gastric cancer, and is also exploring opportunities for combination therapy in areas such as cholangiocarcinoma and triple-negative breast cancer
.
In addition, Jiahe Bio-B rose 11.
72%, the current price is 11.
06 Hong Kong dollars, the average price is 10.
88 Hong Kong dollars, the current turnover is 14.
24 million, the turnover rate is 0.
26%, and the total market value is 5.
438 billion
.
On the news, Jiahe Bio's CDK4/6 inhibitor GB491 (lerociclib) was approved by the NMPA and started a phase III clinical trial: combined with fulvestrant in the treatment of hormone receptor-positive (HR+), human epidermis with disease progression after previous endocrine therapy Growth factor receptor 2-negative (HER2-) patients with locally advanced or metastatic breast cancer
.
This product may start a melee in the domestic CDK4/6 inhibitor in the future
.
As of 10:38, GenScript Biotechnology rose 13.
56%, Zai Lab-SB rose 13.
33%, and Jiahe Bio-B also rose more than 10% , In addition, Nuohui Health-B and others have followed suit
.
Specifically, as of 10:38, GenScript Biotechnology has risen by 13.
56%, the current price is HK$35.
60, the average price is HK$34.
16, the current turnover is 234 million, the turnover rate is 0.
33%, and the total market value is 74.
449 billion
.
On the news, CRO concept stocks have been rising collectively recently.
GenScript Biotechnology recently announced that its biopharmaceutical contract R&D and production organization (CDMO) GenScript Biopharmaceuticals and Hefei Tiangang Immunopharmaceuticals have reached a new antibody drug project cooperation
.
According to the cooperation agreement, GenScript will provide Tiangang Immune with a complete integrated CDMO service from preclinical pharmaceutical development to IND application, and provide a variety of processes such as batch fed culture and perfusion culture to accelerate the IND process.
During the year, 10 CMC projects will be cooperated, and GenScript will be selected as a partner for future clinical and commercial production of related projects
.
JPMorgan Chase has published a report saying that the recent tightening of regulatory policies has no direct fundamental impact on China's healthcare industry, but it has also weakened the industry's market valuation, believing that the adjustment will create investment opportunities
.
The bank believes that the theme of medical regulation is clear, and it is expected to continue to focus on three major themes, namely promoting domestic innovation, improving quality, and improving affordability and accessibility for patients
.
The bank believes that pharmaceutical companies with strong innovation capabilities and management execution are expected to perform well in the long run, and continue to be optimistic about pharmaceutical companies with solid fundamentals and reasonable valuations
.
As of 10:38 on August 23, Zai Lab-SB rose 13.
33%, the current price was HK$1,063, the average price was HK$1,049.
43, the current turnover was 15.
92 million, the turnover rate was 0.
02%, and the total market value was 102.
3 billion
.
The semi-annual report recently disclosed by Zai Lab showed that the company's revenue in the first half of the year increased rapidly, with a year-on-year increase of 197%
.
The rapid growth of revenue is attributable to three products, namely Zele (Niraparib), Aipdun (tumor electric field treatment equipment), and Qingle (ripatinib)
.
Among them, Zele is the company's main product, which brought in sales revenue of US$35.
972 million in the first half of the year, accounting for 63.
1% of the total product revenue, an increase of 71.
8% compared to the same period in 2020
.
The rapid growth in sales is due to the fact that the product entered the National Medical Insurance Drug List (NRDL) in December last year.
The NRDL was officially implemented on March 1 this year.
As of June 30, the number of hospital admissions of Zele was seven times that of the previous one.
reached more than 800
.
It is understood that, in the face of increasingly fierce market competition, the company has confidence in Zele's huge applicable patient group, its ability to be taken orally once a day, and its ability to cross the blood-brain barrier.
Symptoms and opportunities for combination with other drugs
.
For example, Zele is now combined with tebotelimab for clinical research in gastric cancer, and is also exploring opportunities for combination therapy in areas such as cholangiocarcinoma and triple-negative breast cancer
.
In addition, Jiahe Bio-B rose 11.
72%, the current price is 11.
06 Hong Kong dollars, the average price is 10.
88 Hong Kong dollars, the current turnover is 14.
24 million, the turnover rate is 0.
26%, and the total market value is 5.
438 billion
.
On the news, Jiahe Bio's CDK4/6 inhibitor GB491 (lerociclib) was approved by the NMPA and started a phase III clinical trial: combined with fulvestrant in the treatment of hormone receptor-positive (HR+), human epidermis with disease progression after previous endocrine therapy Growth factor receptor 2-negative (HER2-) patients with locally advanced or metastatic breast cancer
.
This product may start a melee in the domestic CDK4/6 inhibitor in the future
.
